Get started
Author

Hasan Daoud

Observed names: Daoud, Hasan, H. Daoud
Observed institution: Boehringer Ingelheim (Germany)
OpenAlex ID: A5041963858
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
2021 · Sanjay Popat, Hyun Ae Jung, et al. · Lung Cancer · 28
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
2022 · Sanjay Popat, Te-Chun Hsia, et al. · The Oncologist · 25
PDF
P50.03 A Real-World Cohort Study of EGFR TKIs in Patients with NSCLC with Uncommon EGFR mutations (UpSwinG)
2021 · S. Miura, T. Hsia, et al. · Journal of Thoracic Oncology · 3
145P UpSwinG: Real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
2021 · S. Miura, T-C. Hsia, et al. · Journal of Thoracic Oncology · 2
PDF
Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
2022 · Tanios S Bekaii-Saab, Sigrid Balser, et al. · Colorectal Cancer · 1
1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)
2021 · S. Popat, H.A. Jung, et al. · Annals of Oncology · 1
Abstract LB138: UpSwinG: real-world, non-interventional cohort study on TKI activity in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations
2021 · Satoru Miura, Te-Chun Hsia, et al. · Cancer Research · 1
P51.05 Sequential Afatinib and Osimertinib in Patients With Advanced EGFRm+ NSCLC and Acquired T790M: The Real-World UpSwinG study
2021 · S. Popat, H.A. Jung, et al. · Journal of Thoracic Oncology
PDF
1217P EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
2021 · S. Miura, T-C. Hsia, et al. · Annals of Oncology
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
2021 · Satoru Miura, Te-Chun Hsia, et al. · Journal of Clinical Oncology
Works count: 11
Citation count: 61
H-index: 3
I10-index: 2
Year
Topic
Type